21-05-2025
ASCO 2025: A Preview of Advancements in Endometrial Cancer
Ursula A. Matulonis, MD, looks ahead to new developments in gynecologic cancers, especially endometrial cancer, that will be presented at ASCO 2025. She highlights a key phase 2 trial testing the anti-PD-L1 drug benmelstobart plus chemotherapy with or without anlotinib and notes interest in its comparison to lenvatinib-based regimens.
Additional noteworthy presentations include data from the DUO-E trial on ctDNA and a triplet-therapy study involving abemaciclib, letrozole, and metformin. Poster sessions will feature emerging treatments like fruquintinib plus sintilimab and the antibody-drug conjugate SHR-A1811. Dr Matulonis also looks forward to phase 3 results in ovarian and cervical cancers, including the KEYNOTE-A18 and ROSELLA studies.
